Results 91 to 100 of about 3,552,558 (305)

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Correction to: Clinical trial recruiters’ experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK

open access: yesTrials, 2021
William J. Cragg   +5 more
doaj   +1 more source

Collective Equipoise, Disappointment and the Therapeutic Misconception: On the Consequences of Selection for Clinical Research [PDF]

open access: yes
Private information induces individuals to self-select as subjects into clinical research trials, and it induces researchers to select which trials they conduct.
Margaret M. Byrne, Peter Thompson
core  

Reciprocal control of viral infection and phosphoinositide dynamics

open access: yesFEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance

open access: yesSystematic Reviews
Our previous guide to estimating hazard ratios (HRs) from published summary (aggregate) data has become very widely used, but many still have difficulties knowing when and how to apply the methods.
Jayne F. Tierney   +2 more
doaj   +1 more source

Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis [PDF]

open access: yes, 2009
In progressive multiple sclerosis (MS) irreversible disability often takes many years to accumulate as a result prolonged trials are required to assess the benefits of therapies.
Chataway, Jeremy   +6 more
core  

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

open access: yesFEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes   +3 more
wiley   +1 more source

Three-outcome designs for external pilot trials with progression criteria

open access: yesBMC Medical Research Methodology
Background Whether or not to progress from a pilot study to a definitive trial is often guided by pre-specified quantitative progression criteria with three possible outcomes.
Duncan T. Wilson   +2 more
doaj   +1 more source

Group sequential designs for negative binomial outcomes

open access: yes, 2018
Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim   +3 more
core   +1 more source

Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation

open access: yesFEBS Letters, EarlyView.
Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy